BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Attention Deficit Hyperactivity Disorder readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Attention Deficit Hyp
 eractivity Disorder\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02736656-10826@assetmemo.bio
DTSTAMP:20261121T005342Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Qelbree (viloxazine): Phase 3 readout est. (NCT02736656)
DESCRIPTION:Qelbree (viloxazine)\, phase 3\, Attention Deficit Hyperactivit
 y Disorder.\nStudy: Open-label Study to Evaluate Long-term Safety and Effi
 cacy of SPN-812 (Viloxazine Extended-release Capsule)\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/viloxazine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT02736656
URL:https://assetmemo.bio/drug/viloxazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07759154-825@assetmemo.bio
DTSTAMP:20261121T005342Z
DTSTART;VALUE=DATE:20270527
DTEND;VALUE=DATE:20270528
SUMMARY:Simtriyo (Centanafadine): Phase 3 readout est. (NCT07759154)
DESCRIPTION:Simtriyo (Centanafadine)\, phase 3\, Attention Deficit Hyperact
 ivity Disorder.\nStudy: A Study to Test the Effects of Centanafadine in Ad
 ults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregula
 tion\nEstimated primary completion: 27 May 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/centanafadine#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07759154
URL:https://assetmemo.bio/drug/centanafadine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07086313-825@assetmemo.bio
DTSTAMP:20261121T005342Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Simtriyo (Centanafadine): Phase 2/3 readout est. (NCT07086313)
DESCRIPTION:Simtriyo (Centanafadine)\, phase 2/3\, Attention Deficit Hypera
 ctivity Disorder.\nStudy: A Trial to Evaluate the Efficacy and Safety of E
 B-1020 in Pediatric Patients With ADHD\nEstimated primary completion: Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/centanafadin
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 086313
URL:https://assetmemo.bio/drug/centanafadine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07087327-825@assetmemo.bio
DTSTAMP:20261121T005342Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Simtriyo (Centanafadine): Phase 3 readout est. (NCT07087327)
DESCRIPTION:Simtriyo (Centanafadine)\, phase 3\, Attention Deficit Hyperact
 ivity Disorder.\nStudy: A Long-term Trial of EB-1020 in Pediatric Patients
  With ADHD\nEstimated primary completion: August 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/centanafadine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07087327
URL:https://assetmemo.bio/drug/centanafadine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678827-10826@assetmemo.bio
DTSTAMP:20261121T005342Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Qelbree (viloxazine): Phase 3 readout est. (NCT07678827)
DESCRIPTION:Qelbree (viloxazine)\, phase 3\, Attention Deficit Hyperactivit
 y Disorder.\nStudy: A Phase 3 Study of Viloxazine ER Capsules in Korean Ch
 ildren and Adolescents With ADHD\nEstimated primary completion: September 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/viloxazine#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07678827
URL:https://assetmemo.bio/drug/viloxazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931080-825@assetmemo.bio
DTSTAMP:20261121T005342Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Simtriyo (Centanafadine): Phase 2/3 readout est. (NCT06931080)
DESCRIPTION:Simtriyo (Centanafadine)\, phase 2/3\, Attention Deficit Hypera
 ctivity Disorder.\nStudy: Evaluation of the Efficacy and Safety of EB-1020
  in Adult ADHD Patients\nEstimated primary completion: December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/centanafadine#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06931080
URL:https://assetmemo.bio/drug/centanafadine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07773883-866@assetmemo.bio
DTSTAMP:20261121T005342Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sunosi (Solriamfetol): Phase 3 readout est. (NCT07773883)
DESCRIPTION:Sunosi (Solriamfetol)\, phase 3\, Attention Deficit Hyperactivi
 ty Disorder.\nStudy: An Open-Label Study to Assess the Long-Term Safety of
  Solriamfetol in Children and Adolescents With ADHD\nEstimated primary com
 pletion: December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/solriamfetol#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07773883
URL:https://assetmemo.bio/drug/solriamfetol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06926829-825@assetmemo.bio
DTSTAMP:20261121T005342Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Simtriyo (Centanafadine): Phase 3 readout est. (NCT06926829)
DESCRIPTION:Simtriyo (Centanafadine)\, phase 3\, Attention Deficit Hyperact
 ivity Disorder.\nStudy: A Long-term Trial of EB-1020 in Adult Patients Wit
 h ADHD\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/centanafadine#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06926829
URL:https://assetmemo.bio/drug/centanafadine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717879-866@assetmemo.bio
DTSTAMP:20261121T005342Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sunosi (Solriamfetol): Phase 3 readout est. (NCT07717879)
DESCRIPTION:Sunosi (Solriamfetol)\, phase 3\, Attention Deficit Hyperactivi
 ty Disorder.\nStudy: Forward Treatment of Attention Deficit and Hyperactiv
 ity Using Solriamfetol (FOCUS-2)\nEstimated primary completion: 30 June 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/solriamfetol#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07717879
URL:https://assetmemo.bio/drug/solriamfetol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717892-866@assetmemo.bio
DTSTAMP:20261121T005342Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sunosi (Solriamfetol): Phase 3 readout est. (NCT07717892)
DESCRIPTION:Sunosi (Solriamfetol)\, phase 3\, Attention Deficit Hyperactivi
 ty Disorder.\nStudy: Forward Treatment of Attention Deficit and Hyperactiv
 ity Using Solriamfetol (FOCUS-3)\nEstimated primary completion: 30 June 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/solriamfetol#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07717892
URL:https://assetmemo.bio/drug/solriamfetol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
